5414002025-04-012025-06-305414002025-04-012025-06-30in-capmkt:OtherExpenses1Member5414002025-04-012025-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRxbrli:pureiso4217:INRxbrli:shares

541400

ZIMLAB

NOTLISTED

INE518E01015

ZIM Laboratories Limited

Main Board

Equity

2025-04-01

2026-03-31

2025-08-07

2025-07-31

INR

Lakhs

Quarterly

First quarter

Single segment

Pharmaceutical

2025-08-07

12:30:00

2025-08-07

19:00:00

Not applicable

false

Not applicable for the reporting period.

2025-04-01

2025-06-30

Unaudited

Standalone

714277000

14756000

729033000

276173000

15930000

7986000

135742000

33035000

47898000

235098000

751862000

-22829000

-5910000

-16919000

-1346000

-18265000

487258000

-0.35

0.0048

0.008

0.0031

Notes 1 The above unaudited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 August 2025 The above results have been subjected to limited review by Statutory Auditor of the Company 2 These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard Ind AS notified under the Companies Indian Accounting Standards Rules 2015 as amended as prescribed under Section 133 of the Companies Act 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India SEBI 3 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures for the year ended 31 March 2025 and the unaudited year to date figures upto 31 December 2024 4 The standalone financial results of the Company for the quarter and year ended 31 March 2025 and quarter ended 30 June 2024 were reviewed audited by another auditor who expressed an unmodified conclusion opinion on those results on 20 May 2025 and 03 August 2024 respectively 5 The Company is principally engaged in a single business segment which is pharmaceuticals There is no separate reportable segment as per Ind AS 108 Operating Segments. <BR> Place Nagpur Anwar S Daud <BR> Date 07 August 2025 Managing Director

Other Expenses

235098000

Measurements of defined employee benefit plans

-1899000

-553000

-1346000